Plain-English translation of NCT07623902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new screening tool called Gixam that analyzes microbes in your mouth to detect pre-cancerous growths or cancer in the colon and rectum. Right now, doctors use a stool test called FIT to screen for colorectal cancer, but some people with early cancer or pre-cancerous polyps can still have a negative FIT result. Researchers want to see if Gixam can catch these cases that FIT misses.
Even when the standard stool screening test comes back negative, some people still have pre-cancer or early cancer in their colon that goes undetected. Gixam may offer an additional screening option to find these cases earlier, when treatment is often more effective.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will provide a sample using the Gixam test (a simple mouth swab), complete a FIT stool test at home that you mail to a lab, and undergo a standard screening colonoscopy. The Gixam results will be compared to what doctors find during your colonoscopy to see how well the new tool works. The entire process happens over a short timeframe around your scheduled colonoscopy appointment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States